A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis
Status:
Terminated
Trial end date:
2011-08-29
Target enrollment:
Participant gender:
Summary
This study assessed the safety and efficacy of Panobinostat as a single agent in the
treatment of Primary Myelofibrosis, Post-Polycythemia Vera and Post-Essential
Thrombocythemia. There were two cohorts - participants with JAK2 mutation and participants
without JAK2 mutation.